Heart failure affects over 6 million people in the US alone. Every year, 660,000 new cases are diagnosed and more than 1 million hospitalizations occur, with a cost approaching $35 billion. For 2 million of these patients (US), drugs can no longer control the problem and, in most cases, the only options remaining are a surgical LVAD or heart transplant. These procedures are risky, invasive, expensive, and considered by cardiologists to be “treatments of last resort” reserved for only the very sickest patients.

Procyrion’s minimally invasive approach to circulatory assist will provide cardiologists with a safe and effective treatment option for the 2 million US patients where no treatment currently exists. Procyrion’s device is the first catheter-deployed, long-term treatment option designed to reduce the workload of the heart, providing an opportunity for the heart to rest and heal. Procyrion’s device dramatically reduces the risks associated with circulatory support devices and will, for the first time, enable treatment of younger and healthier patients before years of progressive damage occur.